Skip to content

Treatment Study Investigating New Cognitive Behavioral Therapy Treatment Manual for Body Dysmorphic Disorder

A Randomized Waitlist Controlled Treatment Trial Investigating CBT for Body Dysmorphic Disorder

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00106223
Enrollment
36
Registered
2005-03-22
Start date
2004-04-01
Completion date
2008-12-01
Last updated
2026-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Body Dysmorphic Disorder, Somatoform Disorders

Keywords

Cognitive Behavioral Therapy, CBT, BDD, Body dysmorphic disorder

Brief summary

In an earlier phase of this study, a cognitive behavioral therapy (CBT) manual to treat body dysmorphic disorder (BDD) symptoms was developed. We are currently implementing this manual-based treatment to validate its effectiveness in patients with BDD.

Detailed description

BDD is a disease that involves preoccupation with imagined or minor physical flaws. The condition often begins in adolescence and, if left untreated, can cause significant social, emotional, and occupational distress. Within the last decade, BDD has received increased attention, and various modes of treatment have been utilized and evaluated. CBT has been found to be a more effective form of treatment than other types of psychotherapy. In this study, we have created a new CBT treatment manual and are currently implementing it to evaluate its effectiveness in patients with BDD. The utility of this manual for different populations will also be evaluated, and adherence and competence measures to assess CBT delivery will be developed. This study will last 24 weeks. Participants will be randomly assigned (like the flip of a coin) to either start CBT treatment immediately or to a waitlist group, which would require a 3-month wait without treatment before beginning treatment for this study. Participants have a 50-50 chance of being in either group. Participants will receive a total of 22 sessions of individual, manual-based CBT. The CBT sessions will occur weekly during the course of the study. During the sessions, participants will receive education about BDD and CBT, engage in activities that help them confront their BDD, learn new ways of thinking about body image, and learn relapse prevention techniques. Self-report scales will be used to assess participants.

Interventions

BEHAVIORALCognitive behavioral therapy (CBT)

Participants will receive a total of 22 sessions of individual, manual-based CBT. The CBT sessions will occur weekly during the course of the study. During the sessions, participants will receive education about BDD and CBT, engage in activities that help them confront their BDD, learn new ways of thinking about body image, and learn relapse prevention techniques.

Sponsors

Massachusetts General Hospital
Lead SponsorOTHER
National Institute of Mental Health (NIMH)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* DSM-IV diagnosis of BDD for at least 6 months prior to study entry * Score higher than 23 on BDD Yale-Brown Obsessive Compulsive Scale * Live within driving distance of Boston, MA or Providence, RI

Exclusion criteria

* Any psychiatric diagnoses other than BDD * Alcohol abuse or dependence within 3 months prior to study entry * Suicidal or homicidal * Psychotropic medication within 2 months prior to study entry

Design outcomes

Primary

MeasureTime frame
Body dysmorphic disorder symptomsMeasured at Months 6 and 9

Secondary

MeasureTime frame
Functioning and life satisfactionMeasured at Months 6 and 9
Depressive symptomsMeasured at Months 6 and 9
Anxiety symptomsMeasured at Months 6 and 9

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORSabine Wilhelm, PhD

BDD Clinic Director, Massachusetts General Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 3, 2026